Press Releases

 
Press Releases
  Date Title and Summary View
May 23, 2017
DUBLIN, HERTFORDSHIRE, England and PITTSBURGH, May 23, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional efficacy and safety data from the three-month, pivotal Phase 3 studies of revefenacin (TD-4208) at the American Tho...
May 17, 2017
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 17, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that data from several studies of revefenacin (TD-4208) will be presented at the American Thoracic Society (ATS) International Conference, whic...
May 16, 2017
HERTFORDSHIRE, England and PITTSBURGH, May 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company will present at the UBS Global Healthcare Conference on Monday, May 22, 2017, in New York City. The presentation is scheduled to begin at 2:30 p.m. ET. Interested par...
May 16, 2017
HERTFORDSHIRE, England and PITTSBURGH, May 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today joins the U.S. Department of Health and Human Services (HHS) Office on Women's Health in recognizing the 18th annual National Women's Health Week. This year's goal is to empower women to make their health a priority and take steps to help improv...
May 10, 2017
HERTFORDSHIRE, England and PITTSBURGH, May 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter ended March 31, 2017. Financial Highlights Total revenues of $2.72 billion, up 24% compared to the prior year period North Ameri...
May 1, 2017
HERTFORDSHIRE, England and PITTSBURGH, May 1, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its Board of Directors has nominated Sjoerd S. Vollebregt as a candidate for election to Mylan's Board at the 2017 Annual Meeting of Shareholders to be held on June 22, 2017. The Board also announced that directors Douglas J. Leech...
Apr 27, 2017
HERTFORDSHIRE, England, and PITTSBURGH, April 27, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Wednesday, May 10, 2017, at 10 a.m. EDT, to review the company's financial results for the first quarter ended March 31, 2017. Mylan will release its financial results on May ...
Apr 20, 2017
HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg, a generic version of the reference listed drug, Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg, originally marketed by Schering. Mylan received final approval fro...
Mar 31, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Meridian Medical Technologies, a Pfizer company and Mylan's manufacturing partner for EpiPen® Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr® (epineph...
Mar 29, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 29, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the successful acquisition of the global rights to the Cold-EEZE® brand cold remedy line from ProPhase Labs, Inc. The transaction provides Mylan all assets and rights relating ...
Page:
1
... NextLast
= add release to Briefcase